Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 5/2016

01.04.2016 | AdisInsight Report

Elbasvir/Grazoprevir: First Global Approval

verfasst von: Gillian M. Keating

Erschienen in: Drugs | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

A fixed-dose combination tablet of the hepatitis C virus (HCV) NS5A inhibitor elbasvir and the HCV NS3/4A protease inhibitor grazoprevir (elbasvir/grazoprevir; Zepatier™) is under development by Merck. Oral elbasvir/grazoprevir 50/100 mg once daily has been approved in the USA for the treatment of adults with chronic HCV genotype 1 or 4 infection. This article summarizes the milestones in the development of elbasvir/grazoprevir leading to this first global approval for chronic HCV genotype 1 or 4 infection.
Literatur
1.
2.
3.
4.
Merck & Co Inc. MSD provides update on European Medicines Agency Marketing Authorization Application for investigational chronic hepatitis C therapy elbasvir/grazoprevir [media release]. 2015. http://​www.​merck.​com. Accessed 9 Feb 2016.
5.
Yeh WW, Caro L, Guo Z, et al. Pharmacokinetics of co-administered HCV protease inhibitor MK-5172 and NS5A inhibitor MK-8742 in volunteers with end-stage renal disease on haemodialysis or severe renal impairment not on haemodialysis [abstract no. 1940]. Hepatology. 2014;60(Suppl 1):1137A.
6.
Yeh WW, Feng HP, Dunnington KM, et al. No clinically meaningful pharmacokinetic interactions between HCV inhibitors grazoprevir/elbasvir with tacrolimus, mycophenolate mofetil, and prednisone, but cyclosprine increases grazoprevir/elbasvir exposures in healthy subjects [abstract no. 725]. Hepatology. 2015;62(Suppl 1):570A–1A.
7.
Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1087–97.CrossRefPubMed
8.
Kawada N, Suzuki F, Karino Y, et al. Efficacy, safety and pharmacokinetics of grazoprevir (MK-5172) and elbasvir (MK-8742) in hepatitis C genotype 1 infected non-cirrhotic Japanese patients (phase 2 portion in phase 2/3 combined study) [abstract no. 707]. Hepatology. 2015;62(Suppl 1):559A.
9.
Jacobson IM, Poordad F, Firpi-Morell R, et al. Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with Child-Pugh class B cirrhosis [abstract no. P049]. Transpl Int. 2015;28(Suppl 2):31–2.
10.
Vierling JM, Kugelmas M, Lawitz E, et al. Efficacy of an eight-week regimen of grazoprevir plus elbasvir with and without ribavirin in treatment-naive, noncirrhotic HCV genotype 1B infection [abstract no. P0769]. J Hepatol. 2015;62(Suppl 2):618.CrossRef
11.
Kwo P, Gane E, Peng CY, et al. Efficacy and safety of grazoprevir/elbasvir +/− RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-EDGE Treatment-Experienced trial [abstract no. P0886]. J Hepatol. 2015;62(Suppl 2):S674–5.CrossRef
12.
Dore G, Altice F, Litwin AH, et al. C-EDGE CO-STAR: efficacy of grazoprevir and elbasvir in persons who inject drugs (PWID) receiving opioid agonist therapy [abstract no. 40]. Hepatology. 2015;62(Suppl 1):227A–8A.
13.
Poordad F, Lawitz E, Gutierrez JA, et al. C-SWIFT: grazoprevir/elbasvir + sofosbuvir in cirrhotic and noncirrhotic, treatment-naive patients with hepatitis C virus genotype 1 infection, for durations of 4, 6 or 8 weeks and genotype 3 infection for durations of 8 or 12 weeks [abstract no. O006]. J Hepatol. 2015;62(Suppl 2):S192–3.CrossRef
14.
Lawitz E, Poordad F, Gutierrez JA, et al. C-SWIFT retreatment (Part B): 12 weeks of elbasvir/grazoprevir with sofosbuvir and ribavirin successfully treated GT1-infected subjects who failed short-duration all-oral therapy [abstract no. LB-12]. Hepatology. 2015;62(6):1386A–7A.
15.
Brown A, Hezode C, Zuckerman E, et al. C-SCAPE: efficacy and safety of 12 weeks of grazoprevir +/− elbasvir +/− ribavirin in patients with HCV GT2, 4, 5 or 6 infection [abstract no. P0771]. J Hepatol. 2015;62(Suppl 2):S619.CrossRef
16.
Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1075–86.CrossRefPubMed
17.
Forns X, Gordon SC, Zuckerman E, et al. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol. 2015;63(3):564–72.CrossRefPubMed
18.
Buti M, Gordon SC, Zuckerman E, et al. Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE. Clin Infect Dis. 2016;62(1):32–6.CrossRefPubMed
19.
Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386(10003):1537–45.CrossRefPubMed
20.
Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir–elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163(1):1–13.CrossRefPubMed
21.
Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2(8):e319–27.CrossRefPubMed
22.
23.
24.
Merck & Co Inc. Merck announces presentation of phase 2 clinical trial results of investigational chronic hepatitis C therapy grazoprevir/elbasvir at the International Liver Congress™ 2015 [media release]. 2015. Accessed 10 Feb 2016.
25.
Dusheiko GM, Manns MP, Vierling JM, et al. Safety and tolerability of grazoprevir/elbasvir in patients with chronic hepatitis C (HCV) infection: integrated analysis of phase 2–3 trials [abstract no. 712]. Hepatology. 2015;62(Suppl 1):562A.
Metadaten
Titel
Elbasvir/Grazoprevir: First Global Approval
verfasst von
Gillian M. Keating
Publikationsdatum
01.04.2016
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 5/2016
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-016-0558-3

Weitere Artikel der Ausgabe 5/2016

Drugs 5/2016 Zur Ausgabe

Review Article

Antipsychotic Management of Schizoaffective Disorder: A Review

Leading Article

Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection

Adis Drug Evaluation

Cobimetinib Plus Vemurafenib: A Review in BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma

Therapy in Practice

The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions

Current Opinion

Two-Drug Treatment Approaches in HIV: Finally Getting Somewhere?

Review Article

Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent